John Allan, MD - Taking a New Look at Mantle Cell Lymphoma in the Era of Novel Agent Classes: From Innovative Concepts to Practical Applications of Evidence

Go online to PeerView.com/TVG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology reviews recent evidence for novel therapeutics for the management of mantle cell lymphoma and offers practical insight on integrating clinical evidence into patient care and management, including for patients who have progressed after upfront therapy and who are candidates for second-line treatment. Upon completion of this activity, participants should be better able to: Cite evidence on the use of newer therapeutics, including BTK inhibitors and immunomodulators, among others, for the management of relapsed/refractory and newly diagnosed MCL, Select regimens with novel components for the management of patients with MCL, Manage therapy-related toxicity in patients with MCL who are receiving treatment with novel therapeutics.